Phase 1 first-in-human (FIH) study of nesvacumab (REGN910) a fully human and selective angiopoietin-2 (Ang2) monoclonal antibody (MAb): Results from hcpatocellular carcinoma (HCC) Cohort.

被引：1

作者：

Kelley, Robin Kate

Siu, Lillian L.

Van Loon, Katherine

Tolcher, Anthony W.

Razak, Albiruni R. A.

Zlyeh, Sharvina

Beeram, Muralidhar

Bedard, Philippe L.

Arcos, Rebecca

Gao, Bo

Trail, Pamela

Adriaens, Lieve

Brownstein, Carrie M.

Lowy, Israel

Papadopoulos, Kyriakos P.

机构：

[1] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[2] Princess Margaret Canc Ctr, Toronto, ON, Canada

[3] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA

[4] START Ctr Canc Care, San Antonio, TX USA

[5] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada

[6] Regeneron Pharmaceut Inc, Tarrytown, NY USA

来源：

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.2540

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2540

引用

页数：1

共 22 条